| 童铭炯.达拉他韦联合阿舒瑞韦治疗失代偿期丙型肝炎肝硬化患者肝功能和肝纤维化影响[J].浙江中西医结合杂志,2019,29(11): |
| 达拉他韦联合阿舒瑞韦治疗失代偿期丙型肝炎肝硬化患者肝功能和肝纤维化影响 |
| Effects of dalatavir combined with asulovir on liver function and fibrosis in patients with decompensated hepatitis C cirrhosisTong Mingjiong Fei Yingming Wu Xinjuan Shaoxing College of Arts and Sciences Department of the 312000 Affiliated Hospital of liver disease |
| 投稿时间：2019-04-03 修订日期：2019-07-01 |
| DOI： |
| 中文关键词: 达拉他韦 阿舒瑞韦 失代偿期丙型肝炎肝硬化 肝功能 肝纤维化 |
| 英文关键词:dalatavir asulovir decompensated hepatitis C cirrhosis liver function liver fibrosis |
| 基金项目: |
|
| 摘要点击次数: 696 |
| 全文下载次数: 6 |
| 中文摘要: |
| 目的：探讨达拉他韦联合阿舒瑞韦治疗失代偿期丙型肝炎肝硬化患者肝功能和肝纤维化影响。方法：选择2017年1月至2018年1月期间我院收治的失代偿期丙型肝炎肝硬化患者98例,按照随机数字表法随机分为对照组与观察组,各49例。对照组患者给予阿舒瑞韦治疗,观察组患者给予达拉他韦联合阿舒瑞韦治疗。两组疗程均为12个月。比较两组治疗前后Child-Pugh评分、肝功能指标和肝纤维化指标变化,及不良反应。结果：两组治疗后Child-Pugh评分、AST、TBil、DBil、ALT、LN、HA、PC-III和IV-C水平较治疗前降低(P<0.05)；观察组治疗后Child-Pugh评分、AST、TBil、DBil、ALT、LN、HA、PC-III和IV-C水平低于对照组(P<0.05)。结论：达拉他韦联合阿舒瑞韦治疗失代偿期丙型肝炎肝硬化患者效果良好,肝功能和肝纤维化指标得到改善,值得临床借鉴。 |
| 英文摘要: |
| Objective: To investigate the effects of dalatavir combined with asulovir on liver function and fibrosis in patients with decompensated hepatitis C cirrhosis. Methods: The 98 patients with decompensated hepatitis C cirrhosis admitted to our hospital from January 2017 to January 2018 were randomly divided into control group and observation group, 49 cases in each group. Patients in the control group were treated with asulovir, while patients in the observation group were treated with dalatavir combined with asulovir. Both groups were treated for 12 months. Child-Pugh score, liver function index, liver fibrosis index and adverse reactions were compared between the two groups before and after treatment. Results: After treatment, the levels of Child-Pugh score, AST, TBil, DBil, ALT, LN, HA, PC-III and IV-C in the two groups were lower before treatment (P<0.05); after treatment, the levels of Child-Pugh score, AST, TBil, DBil, ALT, LN, HA, PC-III and IV-C in the observation group were lower control group (P<0.05). Conclusion: Dalatavir combined with Ashurivir is effective in the treatment of decompensated hepatitis C patients with cirrhosis, and the liver function and liver fibrosis index have been improved, which is worthy of clinical reference. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
